TipRanks
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
US Market
SRPT
Sarepta Therapeutics
RESEARCH TOOLSreports
Want to see SRPT full AI Analyst Report?

Sarepta Therapeutics (SRPT) Stock News & Sentiment

4,071 Followers
Sarepta Therapeutics: ELEVIDYS Data and Revenue Trends Support Continued Sell Rating with Unchanged $5 Price Target
Premium
Ratings
Sarepta Therapeutics: ELEVIDYS Data and Revenue Trends Support Continued Sell Rating with Unchanged $5 Price Target
2d ago
SRPT
Buy Rating Reaffirmed on Elevidys Strength and Long-Term Growth Outlook; $35 Price Target Unchanged
Premium
Ratings
Buy Rating Reaffirmed on Elevidys Strength and Long-Term Growth Outlook; $35 Price Target Unchanged
6d ago
SRPT
Elevidys ENDURE Study Shows Partial Risk Mitigation but Persistent Safety Concerns, Supporting Hold Rating
Premium
Ratings
Elevidys ENDURE Study Shows Partial Risk Mitigation but Persistent Safety Concerns, Supporting Hold Rating
8d ago
SRPT
Sell Rating Reaffirmed on Sarepta as Regulatory Uncertainty Persists; $13 Price Target Maintained
Premium
Ratings
Sell Rating Reaffirmed on Sarepta as Regulatory Uncertainty Persists; $13 Price Target Maintained
9d ago
SRPT
Sarepta Resolves AAVrh74 Gene Therapy Patent Dispute
Premium
Company Announcements
Sarepta Resolves AAVrh74 Gene Therapy Patent Dispute
13d ago
8K
SRPT
Analyst Maintains Buy on Sarepta, Keeping $35 Price Target Amid Confidence in DM1 Franchise and α‑Integrin Delivery Platform
Premium
Ratings
Analyst Maintains Buy on Sarepta, Keeping $35 Price Target Amid Confidence in DM1 Franchise and α‑Integrin Delivery Platform
28d ago
SRPT
Sell Rating Reaffirmed on Weakening Core Franchise and Elevated Clinical Risk; $5 Price Target Unchanged
Premium
Ratings
Sell Rating Reaffirmed on Weakening Core Franchise and Elevated Clinical Risk; $5 Price Target Unchanged
28d ago
SRPT
More SRPT News >

SRPT News on the Web

Buy Rating Reaffirmed on Elevidys Strength and Long-Term Growth Outlook; $35 Price Target Unchanged
TipRanks News
Bullish
Sarepta Resolves AAVrh74 Gene Therapy Patent Dispute
TipRanks News
Neutral
Sarepta Therapeutics, Inc. at Morgan Stanley Global Healthcare Conference Transcript
GuruFocus News
Neutral
Sarepta Stock Slides as Trial Fears Rattle Investors
TipRanks News
Bearish
Analyst Maintains Buy on Sarepta, Keeping $35 Price Target Amid Confidence in DM1 Franchise and α‑Integrin Delivery Platform
TipRanks News
Bullish
FDA Win Sends Sarepta Soaring On Duchenne Gene Bet
TipRanks News
Bullish
Q2 2026 Sarepta Therapeutics Inc Earnings Call Transcript
GuruFocus News
Neutral
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vericel (VCEL), Sarepta Therapeutics (SRPT) and Neumora Therapeutics, Inc. (NMRA)
TipRanks News
Bearish

News Score - Last 7 Days

Neutral
SRPT
Sector Average
Media Buzz
This Week6 articles
Weekly Average4.75 articles
News Sentiment
This Week50%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is SRPT’s Media Buzz Sentiment?
6 articles about SRPT were published this week. In an average week, 4.75 articles are published.
    What is SRPT’s weekly average amount of articles?
    In an average week, 4.75 articles about SRPT are published.
      What is SRPT’s News Sentiment?
      50% of articles about SRPT were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        REGNRegeneron
        QTTBQ32 Bio
        NVSNovartis
        RHHVFRoche Holding AG
        KRROKorro Bio
        Showing the stocks with the most bullish news sentiment over the past week